том 27 издание 4 страницы 921-930

Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization

Тип публикацииJournal Article
Дата публикации2006-04-01
scimago Q2
wos Q2
БС2
SJR0.958
CiteScore6.2
Impact factor2.9
ISSN01969781, 18735169
Biochemistry
Endocrinology
Cellular and Molecular Neuroscience
Physiology
Краткое описание
The melanocortins (MCs) are a family of multifunctional peptidergic hormones. Several superpotent, prolonged acting, enzymatically resistant, MC analogs have been designed and synthesized to help clarify the nature and role of MCs and their receptors (MCRs) in physiological functions. Two of these analogs, a linear peptide, melanotan I, and a cyclic truncated peptide, melanotan II (MTI and MTII, respectively) have been patented and tested clinically for studies on tanning of the skin (MTI) and for diagnosis and treatment of male erectile dysfunction (MTII). A new MTII analog, PT-141 (Palatin Technologies) has initial phase I/II trials and is scheduled to enter pivotal stage III clinical trials leading to commercialization. MTI may provide a therapeutic tan with the potential to lower the risk of skin cancer. PT-141 may improve sexual functionality in both males and females.
Найдено 
Для доступа к списку цитирований публикации необходимо авторизоваться.

Топ-30

Журналы

1
2
3
4
Actas Dermo-Sifiliograficas
4 публикации, 4.65%
Peptides
3 публикации, 3.49%
Journal of Medicinal Chemistry
3 публикации, 3.49%
British Journal of Dermatology
3 публикации, 3.49%
Endocrine Reviews
2 публикации, 2.33%
Dermatology
2 публикации, 2.33%
Dermatologic Surgery
2 публикации, 2.33%
Hautarzt
2 публикации, 2.33%
Journal of Inorganic Biochemistry
2 публикации, 2.33%
Performance Enhancement and Health
2 публикации, 2.33%
Drug Testing and Analysis
2 публикации, 2.33%
Advances in Experimental Medicine and Biology
2 публикации, 2.33%
Journal of Endocrinology
1 публикация, 1.16%
Pharmaceutical patent analyst
1 публикация, 1.16%
Laboratory Animals
1 публикация, 1.16%
Nature Reviews Cancer
1 публикация, 1.16%
Clinical Pharmacokinetics
1 публикация, 1.16%
Cellular and Molecular Life Sciences
1 публикация, 1.16%
Current Sexual Health Reports
1 публикация, 1.16%
International Journal of Molecular Sciences
1 публикация, 1.16%
Advanced Biology
1 публикация, 1.16%
PLoS ONE
1 публикация, 1.16%
European Journal of Pharmaceutics and Biopharmaceutics
1 публикация, 1.16%
Experimental Neurology
1 публикация, 1.16%
Advanced Drug Delivery Reviews
1 публикация, 1.16%
Mendeleev Communications
1 публикация, 1.16%
International Journal of Drug Policy
1 публикация, 1.16%
Journal of the American Academy of Dermatology
1 публикация, 1.16%
Biochemical and Biophysical Research Communications
1 публикация, 1.16%
1
2
3
4

Издатели

2
4
6
8
10
12
14
16
18
20
Wiley
19 публикаций, 22.09%
Elsevier
19 публикаций, 22.09%
Springer Nature
10 публикаций, 11.63%
Taylor & Francis
8 публикаций, 9.3%
American Chemical Society (ACS)
4 публикации, 4.65%
S. Karger AG
3 публикации, 3.49%
MDPI
3 публикации, 3.49%
The Endocrine Society
2 публикации, 2.33%
Ovid Technologies (Wolters Kluwer Health)
2 публикации, 2.33%
Bioscientifica
1 публикация, 1.16%
SAGE
1 публикация, 1.16%
Public Library of Science (PLoS)
1 публикация, 1.16%
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 публикация, 1.16%
American Medical Association (AMA)
1 публикация, 1.16%
IMR Press
1 публикация, 1.16%
2
4
6
8
10
12
14
16
18
20
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
86
Поделиться
Цитировать
ГОСТ |
Цитировать
Hadley M. E., DORR R. T. Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization // Peptides. 2006. Vol. 27. No. 4. pp. 921-930.
ГОСТ со всеми авторами (до 50) Скопировать
Hadley M. E., DORR R. T. Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization // Peptides. 2006. Vol. 27. No. 4. pp. 921-930.
RIS |
Цитировать
TY - JOUR
DO - 10.1016/j.peptides.2005.01.029
UR - https://doi.org/10.1016/j.peptides.2005.01.029
TI - Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization
T2 - Peptides
AU - Hadley, Mac E.
AU - DORR, ROBERT T.
PY - 2006
DA - 2006/04/01
PB - Elsevier
SP - 921-930
IS - 4
VL - 27
PMID - 16412534
SN - 0196-9781
SN - 1873-5169
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2006_Hadley,
author = {Mac E. Hadley and ROBERT T. DORR},
title = {Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization},
journal = {Peptides},
year = {2006},
volume = {27},
publisher = {Elsevier},
month = {apr},
url = {https://doi.org/10.1016/j.peptides.2005.01.029},
number = {4},
pages = {921--930},
doi = {10.1016/j.peptides.2005.01.029}
}
MLA
Цитировать
Hadley, Mac E., and ROBERT T. DORR. “Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization.” Peptides, vol. 27, no. 4, Apr. 2006, pp. 921-930. https://doi.org/10.1016/j.peptides.2005.01.029.